Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing early and late-stage innovative therapies for critical conditions and diseases, ...

Progress in assessing cardiovascular risk and identifying early prevention opportunities, improvements in treating heart failure, new therapies for bleeding strokes, strategies for reducing the ...

40 hours with a standard deviation of .37 hours. "Early recognition of patients with cardiogenic shock allows for prompt treatment initiation," the study authors wrote. "Timely intervention can ...

A cardiovascular specialty hospital in north Texas decreased time to diagnosis for patients with cardiogenic shock by more ...

Due to the positive effects observed in earlier istaroxime studies on cardiac function and blood pressure, WINT is studying ...

Danvers: Johnson & Johnson MedTech, has announced that the U.S. Food and Drug Administration (FDA) has expanded the ...

The patent filing expands upon data obtained from animal model testing and the istaroxime human clinical trials in acute heart failure (AHF) and early cardiogenic shock (ECS), including the latest ...

Phase 1 results support further evaluation of ALLO-316 in patients with CD70-positive clear cell renal cell carcinoma, according to researchers.